[1] Crawford ED. Epidmiology of prostate cancer. Urology, 2003, 62(6 Suppl 1): 3-12.
[2] LuKes M, Urban M, Zalesky M, et al. Prostate-specific antigen: cur-rent status. Folia Biol(Praha), 2001, 47 (2) : 41-49.
[3] Cartledge JJ, Thompson D, Verril H, et al. The stability of free and bound prostate-specific antigen. BJU Int, 1999, 84 (7) : 810-814.
[4]

托马斯. 临床实验诊断学: 实验结果的应用和评估. 上海: 上海科学技术出版社, 2004: 960-961.
[5] Caplan A, Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol, 2002, 117 (suppl) : S104-S108.
[6] 张晓春, 那彦群, 郭应禄. 前列腺特异性抗原普查在诊断前列腺癌中的作用. 中华泌尿外科杂志, 2000, 21 (1) : 37-40.  doi: 10.3760/j:issn:1000-6702.2000.01.015
[7] Stenman UH, Leinonen J, Alfthan H. A complex between prostate-specific antigen and alpha1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assays of the complex improves clinical sensitivity for cancer. Cancer Res, 1991, 51 (1) : 222-226.